Evidence map›Paper›PMID 39238388›Full record

ReviewCurrent medicinal chemistry2025

Molecular Modeling Insights on the Pharmaceuticals and Hypotheses of Alzheimer's Disease.

Alexandre A de Castro, Henrique F Silva, Maria V F P Garcia, Paula Homem-de-Mello, Teodorico C Ramalho

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alexandre A de CastroCenter for Natural and Human Sciences, Federal University of ABC, Santo André, 09280-560, Brazil.
Henrique F SilvaDepartment of Chemistry, Federal University of Lavras, Lavras, 37200-000, Brazil.
Maria V F P GarciaCenter for Natural and Human Sciences, Federal University of ABC, Santo André, 09280-560, Brazil.
Paula Homem-de-MelloCenter for Natural and Human Sciences, Federal University of ABC, Santo André, 09280-560, Brazil.
Teodorico C RamalhoDepartment of Chemistry, Federal University of Lavras, Lavras, 37200-000, Brazil.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico - Brazil (CNPq) 371610/2023-0, 305381/2022-9, 150744/2022-6Financiadora de Estudos e Projetos - Brazil (FINEP) 0038/21, 0288/22Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2024/01071-3
6 · The paper itself

Abstract

Alzheimer's disease (AD) stands as the predominant contributor to dementia cases. The ongoing developments in our understanding of its pathogenesis have sparked the interest of researchers, driving them to explore innovative treatment approaches. Existing therapies incorporating cholinesterase inhibitors and/or NMDA antagonists have shown limited improvement in alleviating symptoms. This, in turn, highlights the urgency for the pursuit of more effective therapeutic options. Given the annual rise in the number of individuals affected by dementia, it is imperative to allocate resources and efforts towards the exploration of novel therapeutic options. This review aims to provide a comprehensive overview of the AD-related hypotheses, along with the computational approaches employed in research within each hypothesis. In this comprehensive review, the authors shed light on using various computational tools, including diverse case studies, in the pursuit of finding efficacious treatments for AD. The development of more sophisticated diagnostic techniques is crucial, enabling early detection and intervention in the battle against this challenging condition. The potential treatments investigated in this analysis are poised to assume ever more significant functions in both preventing and treating AD, ultimately enhancing the management of the condition and the overall well-being of individuals affected by AD.

Indexed as

Alzheimer DiseaseCholinesterase InhibitorsHumansModels, MolecularCholinesterase InhibitorsAD-related hypothesesAlzheimer’s diseaseamyloid-betacomputational approaches.neuroinflammationtau protein

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.